It is possible that unique differences in dietary patterns or intestinal or microbial metabolism could contribute to these PBH-specific metabolic responses
GLP-1 receptor agonists emerge as promising therapies for MASLD, addressing metabolic dysfunction and offering potential improvements in liver health and fibrosis management
Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably
Navigating Postpartum weight loss: Evidence and interventions
Semaglutide has the longest safety record and the SELECT trial proving cardiovascular benefits
Get Shapely Blog
